U.S. markets open in 4 minutes
  • S&P Futures

    4,570.25
    +5.00 (+0.11%)
     
  • Dow Futures

    35,686.00
    +42.00 (+0.12%)
     
  • Nasdaq Futures

    15,578.75
    +33.75 (+0.22%)
     
  • Russell 2000 Futures

    2,286.10
    -7.80 (-0.34%)
     
  • Crude Oil

    83.19
    -1.46 (-1.72%)
     
  • Gold

    1,796.20
    +2.80 (+0.16%)
     
  • Silver

    24.16
    +0.07 (+0.30%)
     
  • EUR/USD

    1.1624
    +0.0022 (+0.19%)
     
  • 10-Yr Bond

    1.5680
    -0.0510 (-3.15%)
     
  • Vix

    15.93
    +0.69 (+4.53%)
     
  • GBP/USD

    1.3732
    -0.0032 (-0.23%)
     
  • USD/JPY

    113.6190
    -0.5100 (-0.45%)
     
  • BTC-USD

    59,099.11
    -3,470.63 (-5.55%)
     
  • CMC Crypto 200

    1,419.89
    -85.26 (-5.66%)
     
  • FTSE 100

    7,264.86
    -12.76 (-0.18%)
     
  • Nikkei 225

    29,098.24
    -7.77 (-0.03%)
     

FDA Gives Accelerated Approval to Seagen - Genmab's ADC In Cervical Cancer

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • The FDA handed an accelerated approval to Seagen Inc (NASDAQ: SGEN) and Genmab A/S’ (NASDAQ: GMAB) Tivdak (tisotumab vedotin-tftv, or TV).

  • The nod comes for second-line patients with recurrent or metastatic cervical cancer who previously progressed after chemotherapy rather than PD-(L)1 systemic therapy.

  • Read Next: Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer.

  • Tivdak is an antibody-drug conjugate (ADC) that links a tissue factor-directed antibody with a payload of monomethyl auristatin E.

  • The agency based its review on data from the Phase II innovaTV 204 study in 101 patients, with Tivdak posting a 24% response rate, with a median duration of response of 8.3 months.

  • Seagen and Genmab will run a confirmatory trial to determine the drug’s clinical outcomes.

  • The drug will come with a black box warning for ocular toxicity, which includes a risk of changes in the corneal epithelium and conjunctiva, resulting in vision changes, including severe vision loss and corneal ulceration to the drug’s label.

  • Related content: Benzinga's Full FDA Calendar.

  • Price Action: SGEN stock closed 1.82% higher at $159.06 on Monday, while GMAB shares are up 2.93% at $44.20 during the premarket session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.